Literature DB >> 30299248

Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study.

Garifallia Sakellariou1, Giovanni Lombardi2, Barbara Vitolo1, Marta Gomarasca2, Martina Faraldi2, Roberto Caporali1, Giuseppe Banfi3, Carlomaurizio Montecucco4.   

Abstract

OBJECTIVES: We aimed to evaluate the correlation between serum calprotectin and clinical and ultrasonographic (US) variables in early-onset psoriatic arthritis (PsA) and controls with rheumatoid arthritis (RA).
METHODS: In a retrospective cross-sectional study, including PsA and matched RA patients, 44 joint counts (TJC, SJC), calprotectin, ESR and CRP were measured. US of wrists and MCPs 1-5 was performed, with grey-scale (GS) and power Doppler (PD) scored 0-3 at each site, summed in a total score. The correlation between calprotectin, clinical and US variables was evaluated by Spearman's coefficient, the predictivity by calprotectin of US by regression. Secondary analyses separating polyarticular PsA and using different US definitions (GS>1, PD>1) were performed.
RESULTS: 78 PsA and 78 RA were included (PsA male 32%; mean age 51.7 (13.5)). Calprotectin did not significantly differ in PsA and RA. In PsA, calprotectin correlated with GS score (ρ=0.340, p=0.008), PD score (ρ=0.292, p=0.023) and the presence of PD (ρ=0.263, p=0.042); in RA there were no significant correlations. In polyarticular PsA, a significant correlation between calprotectin and GS (ρ=0.369, p=0.019) and PD scores (ρ=0.363, p=0.021) was confirmed. In both PsA and RA, calprotectin and CRP significantly correlated, while SJC and TJC did not. In the regression analysis, calprotectin did not predict US variables in PsA. Similar results were achieved in RA.
CONCLUSIONS: In early PsA, serum calprotectin correlates with US measures of disease activity. Our results provide preliminary evidence for the application of this biomarker in early PsA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30299248

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Circulating Calprotectin as a Biomarker of COVID-19 Severity.

Authors:  Michael Mahler; Pier-Luigi Meroni; Maria Infantino; Katherine A Buhler; Marvin J Fritzler
Journal:  Expert Rev Clin Immunol       Date:  2021-04-13       Impact factor: 4.473

Review 2.  Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review.

Authors:  Philip J Mease; Mohit Kumar Bhutani; Steven Hass; Esther Yi; Peter Hur; Nina Kim
Journal:  Rheumatol Ther       Date:  2021-12-28

3.  Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis.

Authors:  Isaac T Cheng; Huan Meng; Martin Li; Edmund K Li; Priscilla C Wong; Jack Lee; Bryan P Yan; Alex P W Lee; Ho So; Lai-Shan Tam
Journal:  Front Med (Lausanne)       Date:  2022-07-08

4.  In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis.

Authors:  Garifallia Sakellariou; Silvana Quaglini; Serena Bugatti; Francesca Bobbio-Pallavicini; Vittorio Gabba; Carlomaurizio Montecucco
Journal:  J Clin Med       Date:  2021-06-27       Impact factor: 4.241

5.  Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.

Authors:  Matthias Jarlborg; Delphine S Courvoisier; Céline Lamacchia; Laura Martinez Prat; Michael Mahler; Chelsea Bentow; Axel Finckh; Cem Gabay; Michael J Nissen
Journal:  Arthritis Res Ther       Date:  2020-05-06       Impact factor: 5.156

6.  Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients.

Authors:  Marco Diani; Silvia Perego; Veronica Sansoni; Lucrezia Bertino; Marta Gomarasca; Martina Faraldi; Paolo Daniele Maria Pigatto; Giovanni Damiani; Giuseppe Banfi; Gianfranco Altomare; Giovanni Lombardi
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.